X0202 SCHEDULE 13G/A 0001140361-24-008104 0001858703 XXXXXXXX LIVE 2 Common Shares, no par value 06/30/2026 0001980845 enGene Therapeutics Inc. 29286X101 4868 Rue Levy, Suite 220 Saint-Laurent Quebec Z4 H4R 2P1 Rule 13d-1(b) Blue Owl Capital Holdings LP DE 511177.00 0.00 511177.00 0.00 511177.00 0.76 PN The reported securities represent 511,177 Common Shares issuable upon exercise of warrants to each acquire one Common Share ("Warrants"). The reported percentage is calculated based on 66,989,466 Common Shares outstanding as of June 9, 2026, as reported on the Issuer's 10-Q filed with the Securities and Exchange Commission on June 15, 2026, and as increased by the 511,177 Common Shares issuable upon exercise of the Warrants. enGene Therapeutics Inc. 4868 Rue Levy, Suite 220, Saint-Laurent, Quebec, Canada, H4R 2P1 This Statement is filed by Blue Owl Capital Holdings LP, referred to herein as the "Reporting Person." 399 Park Avenue, New York, New York 10022 See response to row 4 on the cover page hereto. N IA See response to row 9 on the cover page hereto. Pursuant to Rule 13d-4 of the Act, the Reporting Person declares that filing this Statement shall not be deemed an admission that the Reporting Person is a beneficial owner of the reported securities, for purposes of Section 13(d) and/or Section 13(g) or for any other purpose. See response to row 11 on the cover page hereto. See response to row 5 on the cover page hereto. See response to row 6 on the cover page hereto. See response to row 7 on the cover page hereto. See response to row 8 on the cover page hereto. N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Blue Owl Capital Holdings LP /s/ Karen Hager 08/12/2026